Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies

被引：31

作者：

Abdou, Yara ^{[1
]}

Pandey, Manu ^{[1
]}

Sarma, Maithreyi ^{[1
]}

Shah, Shrunjal ^{[1
]}

Baron, Jeffrey ^{[2
]}

Ernstoff, Marc S. ^{[1
]}

机构：

[1] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY 14263 USA

[2] Roswell Park Comprehens Canc Ctr, Dept Pharm, Buffalo, NY USA

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2020年 / 86卷 / 09期

关键词：

checkpoint inhibitor; CTLA-4; immune checkpoints; immunotherapy; PD-1; PD-L1; resistance; SQUAMOUS-CELL CARCINOMA; JAVELIN SOLID TUMOR; INDOLEAMINE 2,3-DIOXYGENASE; ARGININE DEPRIVATION; ANTITUMOR-ACTIVITY; T-CELLS; MACROPHAGE ACTIVATION; RESISTANCE MECHANISM; METASTATIC MELANOMA; NEGATIVE REGULATION;

D O I：

10.1111/bcp.14316

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Immune checkpoints are cell surface molecules that initiate regulatory pathways which have powerful control of CD8(+) cytolytic T cell activity. Antagonistic and agonistic antibodies engaging these molecules have demonstrated profound impact on immune activation and have entered clinical use for the treatment of a variety of diseases. Over the past decade, antagonistic antibodies known as immune checkpoint inhibitors have become a new pillar of cancer treatment and have reshaped the therapeutic landscape in oncology. These agents differ in their mechanism of action and toxicity profiles compared to more traditional systemic cancer treatments such as chemo- and targeted therapies. This article reviews the pharmacology of this new class of agents.

引用

页码：1690 / 1702

页数：13

共 149 条

[1] Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia [J].

Abdel-Wahab, Omar ;

Levine, Ross L. .

BLOOD, 2013, 121 (18) :3563-3572

[2] Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy [J].

Agrawal, Shruti ;

Feng, Yan ;

Roy, Amit ;

Kollia, Georgia ;

Lestini, Brian .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4

[3] Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs [J].

Allard, Bertrand ;

Pommey, Sandra ;

Smyth, Mark J. ;

Stagg, John .

CLINICAL CANCER RESEARCH, 2013, 19 (20) :5626-5635

[4]

[Anonymous], 2019, SITC 33 ANN M

[5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[6] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[7] Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application [J].

Ascierto, Paolo A. ;

Marincola, Francesco M. ;

Ribas, Antoni .

JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9

[8] CHARACTERIZATION OF THE LYMPHOCYTE-ACTIVATION GENE 3-ENCODED PROTEIN - A NEW LIGAND FOR HUMAN-LEUKOCYTE ANTIGEN CLASS-II ANTIGENS [J].

BAIXERAS, E ;

HUARD, B ;

MIOSSEC, C ;

JITSUKAWA, S ;

MARTIN, M ;

HERCEND, T ;

AUFFRAY, C ;

TRIEBEL, F ;

PIATIERTONNEAU, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (02) :327-337

[9] Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status [J].

Baverel, Paul G. ;

Dubois, Vincent F. S. ;

Jin, Chao Yu ;

Zheng, Yanan ;

Song, Xuyang ;

Jin, Xiaoping ;

Mukhopadhyay, Pralay ;

Gupta, Ashok ;

Dennis, Phillip A. ;

Ben, Yong ;

Vicini, Paolo ;

Roskos, Lorin ;

Narwal, Rajesh .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (04) :631-642

[10] Activation rules: the two-signal theories of immune activation [J].

Baxter, AG ;

Hodgkin, PD .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :439-446

← 1 2 3 4 5 6 7 8 9 10 →